Actively Recruiting
SGLT2 Inhibitors in Geographic Atrophy
Led by Washington University School of Medicine · Updated on 2025-12-18
70
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.
CONDITIONS
Official Title
SGLT2 Inhibitors in Geographic Atrophy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to give signed informed consent and comply with study requirements
- Willing and reliable to participate for the entire study duration and follow study procedures
- Male or female who is surgically sterilized or amenorrheic for at least one year
- 50 years old or older
- Have dry advanced AMD with non-foveal geographic atrophy
- Geographic atrophy area between 2.5 mm2 and 17.5 mm2
- At least one lesion of geographic atrophy is 1.25 mm2 or larger if multiple lesions
- Best corrected visual acuity between 20/25 and 20/320
- No prior treatments for AMD except oral supplements
You will not qualify if you...
- Used investigational drugs within 60 days
- Currently using other SGLT2 inhibitors
- History of symptomatic hypotension or low blood pressure with symptoms
- Diagnosis of type 1 or type 2 diabetes mellitus
- End stage kidney disease or low kidney filtration rate (eGFR less than 25 mL/min/1.73 m2)
- History of heart failure
- Serious allergy to dapagliflozin or its ingredients
- Other medical, psychiatric, or substance abuse conditions interfering with study participation
- Prior AMD treatments or intravitreal treatments except oral supplements
- Eye surgery or laser treatment within 3 months before randomization
- Eye infections or surface inflammation in the past 12 weeks
- Prior thermal laser treatment in the macular area
- Signs of choroidal neovascularization in the study eye
- Enrolled in another interventional clinical trial during this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
E
Eve Adcock
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here